Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

NCT00440193 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00440193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00440193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
April 30, 2010
Enrollment
3,449 (actual)
Sites
324

Conditions

As the registry lists them; a condition with its own page is linked.

venous thrombosis